The transformation of BioNTech from a pandemic-era household name into a dedicated oncology powerhouse is gathering speed, with the stock rallying more than 22% over the past month to trade near €92. The shares have comfortably cleared their 50-day moving average, even as a modest daily dip of nearly 2% on Tuesday barely registered against the broader upward trajectory.
A Pancreatic Cancer Milestone That Turned Heads
The most powerful catalyst for the recent surge came from the AACR Congress in 2026, where BioNTech and partner Genentech unveiled long-term follow-up data on autogene cevumeran (BNT122), an individualized mRNA cancer vaccine for patients with resected pancreatic ductal adenocarcinoma. The results were striking: of 16 trial participants, eight mounted a strong T-cell response to the vaccine. Seven of those eight patients remain alive and recurrence-free six years after surgery. By contrast, among the eight patients who showed no measurable immune reaction, only two survived the same period, with a median survival of just 3.4 years.
Pancreatic cancer is among the most lethal malignancies, making these durable remissions clinically noteworthy even if the sample size remains small. The data underscore why the market is willing to bet on a pipeline that, as yet, generates no revenue from oncology products.
Fifteen Phase 3 Trials by Year-End
BioNTech’s ambition extends well beyond this single vaccine. Management has set a target of running 15 Phase 3 oncology studies by the end of 2026, with the first cancer products expected to reach the market this year. By 2030, the company aims to establish itself as a diversified leader in tumor treatment.
Central to this push is the antibody BNT327, known as Pumitamig, being developed in partnership with Bristol Myers Squibb. The collaboration is advancing pivotal trials in non-small cell lung cancer and triple-negative breast cancer. Success could unlock milestone payments exceeding $10 billion, plus a 50% profit share.
Cost Discipline Meets a €17 Billion War Chest
While the clinical ambitions are expansive, BioNTech is simultaneously tightening its operational belt. The mRNA vaccine facility in Singapore, acquired during the pandemic, will close by February 2027, eliminating around 85 jobs. Management cited a comprehensive network analysis that concluded the site no longer fits the long-term strategy.
Should investors sell immediately? Or is it worth buying BioNTech?
The cost-cutting comes against a backdrop of financial strain: the company posted a net loss of €1.14 billion in fiscal 2025. Yet the balance sheet remains formidable, with roughly €17 billion in cash and liquid securities providing ample runway for expensive research programs. Analysts at Morgan Stanley, who rate the stock a buy with a $126 price target, note that a series of promising clinical readouts are due in the coming months.
Analyst Divergence and the Leadership Question
Wall Street is broadly constructive but not uniformly bullish. Goldman Sachs recently upgraded BioNTech to “Buy” with a $142 target, while Citigroup and H.C. Wainwright each peg fair value at $130. BMO Capital, however, trimmed its target from $143 to $128, flagging risks that other houses may be underweighting.
The core tension is that BioNTech expects no oncology revenue in 2026, while its Covid-related income stream continues to shrink. Investors are effectively placing a long-term bet on a pipeline that has yet to generate a single dollar of commercial cancer sales.
Adding to the uncertainty, the company faces a leadership transition. Founders Ugur Sahin and Özlem Türeci plan to step back by year-end to launch a new independent mRNA venture. BioNTech is already searching for successors, and the market will be watching closely for clarity on the succession timeline.
What to Watch on May 5
All eyes now turn to May 5, 2026, when BioNTech reports first-quarter results. Alongside the financials, investors expect concrete updates on the regulatory filing timeline for the antibody-drug conjugate BNT323, as well as further details on the leadership handover. The quarterly print will serve as an early test of whether the market’s enthusiasm for BioNTech’s oncology pivot can withstand the near-term absence of product revenue and the uncertainty of a founder exit.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 23 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 23.
BioNTech: Buy or sell? Read more here...
